News
-
California-based simulation and modeling software company Simulations Plus has announced that it will join the SimInhale COST (European Cooperation in Science and Technology) Action consortium, which aims to “advance particle designs for improved deposition and… Read more . . .
-
The US Patent and Trademark Office (USPTO) has awarded US Patent No. 9,446,134 (“Stabilizing alkylglycoside compositions and methods thereof”) to Aegis Therapeutics, the company said. The patent covers an intranasal formulation of octreotide, which is… Read more . . .
-
According to an FDA drug shortages report, the US shortage of sumatriptan nasal spray due to a shortage of active ingredient that was first reported in November 2015 should be completely resolved by February 2017.… Read more . . .
-
According to Windtree Therapeutics, its Aerosurf inhaled lucinactant for the treatment of premature infants with respiratory distress syndrome (RDS) has received Fast Track designation from the FDA. Aerosurf is currently in Phase 2 development, with… Read more . . .
-
Purdue Pharma Canada will pay up to $3 million Canadian to Medical Developments International Limited (MDI) for Canadian rights to MDI’s Penthrox methoxyflurane inhaler for the treatment of moderate to severe pain in trauma patients,… Read more . . .
-
According to Evoke Pharma, the company held a pre‑NDA meeting with the FDA about its intranasal metocopramide for the treatment of diabetic gastroparesis in adult women and now believes that it will be able to… Read more . . .
-
Capsugel has announced that it will add both pilot and commercial scale micronization capacity at a facility in Quakertown, PA which it acquired as part of its acquisition of Powdersize in January 2016. New equipment… Read more . . .
-
Bepak parent company Consort Medical has announced a multi-year agreement with AstraZeneca to supply Bespak’s MDI valves and actuators for use in AstraZeneca’s Bevespi Aerosphere inhaler. The components for the project, which will be called… Read more . . .
-
Raptor Pharmaceutical has presented results from a network meta-analysis of data from clinical trials of inhaled tobramycin, colistimethate sodium, aztreonam and levofloxacin for the treatment of P. aeruginosa lung infections in CF patients. The data,… Read more . . .
-
Patara Pharma has announced Phase 2 results for its PA101 inhaled treatment for refractory chronic cough in patients with idiopathic pulmonary fibrosis (IPF) showing that patients receiving PA101 experienced a statistically significant reduction in cough… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.